Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07443371

Effect of Transfer Energy Capacitive and Resistive Therapy on Palmar Fibromatosis

The objective of the present study is to explore the effect of Transfer Energy Capacitive and Resistive Therapy (TECAR) therapy on pain, range of motion (ROM) and hand function in dupuytren's contracture patients (palmar fibromatosis).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Palmar Fibromatosis Connective Tissue Diseases Contracture Dupuytren Contracture Fibroma Muscular Diseases Musculoskeletal Diseases Neoplasms Neoplasms by Histologic Type Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms, Fibrous Tissue Skin and Connective Tissue Diseases

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Peter Milad Haroun

Cairo, Egypt

About this study

Dupuytren contracture is a benign, progressive disease of the palmar fascia which results in shortening, thickening, and fibrosis of the fascia and aponeurosis of the palm driven by myofibroblastic proliferation.

TECAR therapy is considered a special form of energy that uses frequencies between 300 KHz and 1 MHz and is characterized as a non-invasive high-frequency energy that awakens the body's natural ability to self-regenerate.

The TECAR therapy can work in two modes of electric charge transfer: capacitive and resistive mode. The reactions produced by the capacitive system through the capacitive electrode are focused on tissues with higher electrolyte content, such as soft tissues and muscles, as opposed to the resistive system that focuses on larger and more resistant tissues such as tendons, bones and articulations. With these two modes of energy transfer, the therapy allows an increase in vasodilation, oxygenation, increase in microcirculation and increase in internal temperature. So, this study aimed to to explore the effect of Transfer Energy Capacitive and Resistive Therapy (TECAR) therapy on pain, range of motion (ROM) and hand function in dupuytren's contracture patients (palmar fibromatosis).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages of patients will be ranged from 40 to 70 years.
  • Presence of palpable cords and/or digital contracture ≥ 20° at the metacarpophalengeal joint or Proximal interphalengeal joint joints .
  • Clinical diagnosis confirmed by a hand surgeon or relevant specialist.
  • All patients will enter the study having their informed consent

Exclusion criteria

  • Patient with severe contracture >30° or multiple digit involvement requiring surger.
  • History of surgical release (fasciotomy, fasciectomy) or collagenase injection in the affected hand.
  • Presence of infection, ulceration, or skin lesions on the treatment area.
  • Presence of pacemakers, metal implants, or other electronic implants in the treatment area.
  • Active cancer or tumor in the treatment region.
  • Pregnancy.
  • Conditions such as stroke, Parkinson's disease, or rheumatoid arthritis that may confound results.
  • Cognitive impairment, psychiatric illness, or other barriers to protocol adherence

Treatment and study plan

Transfer Energy Capacitive and Resistive (TECAR) therapy

Device

The apparatus used is comprised of a generator that supplies a signal at the frequency of 0.5 MHz and a maximum power of 300 watts (HCR900).The power can be regulated by controlling the quantity of transferred energy and the relative biological action. The counter electrode (Return Plate) that closes the circuit consists of a metal plate that is applied in opposition or a cylinder that is clasped.

The head of the device will be applied over the treated area for 20 minutes (min) (10 min of capacitive head and 10 min of resistive head), moderate to high intensity. It will be applied along and in circles over the affected palm, 3 sessions weekly for 6 weeks.

traditional therapy

Other

The patients will receive the traditional physical therapy program 3 sessions / week , for 6 weeks totally.

It consists of stretching exercise, flexor tendon glide and splinting.

Primary outcomes

  1. Active range of motion (ROM) assessment of metacarpophalangeal joint (MCP):

    Time frame: 6 weeks

    • Patient Position: Sitting on a chair while his/her forearm will be in a mid position and supported with the involved hand on the plinth beside him/her.
    • The therapist will stabilize the metacarpal bone.
    • The goniometer axis will be placed over the dorsal surface of the MCP joint. The stationary arm of the goniometer will be placed parallel to the longitudinal axis of the metacarpal bone and the movable arm of the goniometer will be placed parallel to the longitudinal axis of the proximal phalanx.
    • The patient will be asked to flex then extend his MCP joint to the limit of the motion (normally 0º-100º extension-flexion) then range of motion (ROM) will be documented.

  2. Active range of motion (ROM) assessment of proximal interphalangeal joint (PIP):

    Time frame: 6 weeks

    • Patient Position: Sitting on a chair while his/her forearm will be in a mid position and supported with the involved hand on the plinth beside him/her.
    • The therapist will stabilize the proximal phalanx.
    • The goniometer axis will be placed over the dorsal surface of the PIP joint. The stationary arm of the goniometer will be placed parallel to the longitudinal axis of the proximal phalanx and the movable arm of the goniometer will be placed parallel to the longitudinal axis of the middle phalanx.
    • The patient will be asked to flex then extend his PIP joint to the limit of the motion (normally 0º-100º extension-flexion) then range of motion ROM will be documented.

  3. Pain intensity measurement

    Time frame: 6 weeks

    The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 'no pain at all' and 'pain as bad as it could be'.

    The patient is asked to mark his pain level on the line between the two endpoints. The distance between 'no pain at all' and the mark then defines the subject's pain From 0 to 10 , (0 )means no pain and up to (10) means intolerable pain

Secondary outcomes

  1. The Southampton Dupuytren's Scoring Scale

    Time frame: 6 weeks

    The Southampton Dupuytren's Scoring Scheme (SDSS) is a 5-item, 20-point patient-reported outcome measure (PROM) developed in 2014 to assess functional disability from Dupuytren's disease. It measures impairment across personal, domestic, work, and hobby activities, with scores from 0 (no problem) to 20 (worst), offering high sensitivity to change.

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmed Zarraa, PHD

CONTACT

[email protected]

01007580084

Peter Haroun, Master

CONTACT

[email protected]

01289951508

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 2, 2026
Registry last updated
Mar 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.